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Background: The emergence of artemisinin resistance in the Greater Mekong Subregion (GMS) has prompted
urgent containment measures. One possible approach is mass drug administration (MDA). This article explores
attitudes towards and perceptions of MDA for malaria elimination among policymakers and leading
malariologists.
Methods: Thirty-two semistructured interviews (SSI) were conducted with policymakers (n=17) and principal
investigators (n=15) selected based on their involvement in malaria prevention, control and elimination in the
GMS. Interviews were audio recorded and transcribed for qualitative content (thematic) analysis using NVivo
(QSR International, Doncaster, Victoria, Australia).
Results: Researchers and policymakers described reluctance and consequently delays to pilot MDA for malaria
elimination. Most policymakers and some researchers reported concerns around the evidence base, citing a
lack of data on its effectiveness and appropriate target populations. There were also worries about promoting
resistance. Other issues included a previous lack of support from the World Health Organization, past MDAs,
the remoteness of target populations and challenges explaining the rationale for MDA.
Conclusions: The complex rationale for MDA for malaria elimination, mistaking pilot studies for implementa-
tion, past experiences with MDA, difﬁculties in selecting appropriate sites and the WHO’s lack of clear backing
undermined the support for MDA for malaria elimination.
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Introduction
Over the last century, malaria parasites have developed resistance
to every antimalarial.1 Quinine, one of the ﬁrst antimalarials dis-
covered, was used as the only available drug for Plasmodium fal-
ciparum outside of Asia for slightly less than 300 y, when ﬁnally
resistance was described in 1911.2 Later, resistance to chloroquine
developed within only 12 y from its ﬁrst use as a treatment in
1945. Resistance to proguanil developed within 1 y of its initial use
in 1948.3 Subsequently, pyrimethamine, which was introduced in
1952, could not be used as monotherapy due to cross-resistance
with proguanil,2 and resistance to sulfadoxine–pyrimethamine (SP)
developed within the same year of its introduction in 1967.3
Resistance to meﬂoquine, which subsequently replaced SP in 1977
as a ﬁrst-line treatment, also developed within 5 y.4 During the
1990s, resistance to atovaquone developed within 1 y of its use.5
Since 2004, artemisinin combination therapy (ACT) has been in
use as a ﬁrst-line treatment in many countries. Resistance to ACT
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was ﬁrst reported in 2008.6 Currently there are no alternative anti-
malarials to replace ACT.
The emergence of artemisinin-resistant malaria in the
Greater Mekong Subregion (GMS) has added urgency to efforts
to eliminate falciparum malaria and contain the spread of
resistant strains towards Africa.7–11 The threat of a public health
emergency if multidrug-resistant malaria reaches Africa has
prompted scientists to consider approaches to accelerate elim-
ination in addition to the basic control tools currently used in
malaria prevention and control programmes.
In low to moderate transmission areas of the GMS, scientists
are evaluating mass drug administration (MDA) as part of a
multipronged approach to malaria elimination.12–14 This strat-
egy, termed targeted malaria elimination (TME),1 aims to inter-
rupt the transmission of falciparum malaria from foci where
artemisinin resistance has been identiﬁed. In TME, all members
of the target communities, whether infected or not, are offered
antimalarial treatment. Recent pilot studies of TME consisted of
dihydroartemisinin piperaquine (DHA-PPQ) for 3 d and a single
low-dose primaquine every month for 3 months. A recent sys-
tematic review on the safety and efﬁcacy of DHA-PPQ showed
that there was no increased risk with its use.15 The MDA is com-
plemented by rigorous implementation of conventional malaria
control activities, including the distribution of long-lasting
insecticide-treated bed nets.1,16 The MDA approach is widely
used to control several neglected tropical diseases, including
lymphatic ﬁlariasis.17
In the past, MDA has been used in malaria control pro-
grammes, but its wider uptake in policy has been limited by the
perceived risk of drug resistance18 and difﬁculties with implemen-
tation, speciﬁcally the requirement of high coverage in target
communities.1,19,20 The most prominent concern about frequent
and large-scale MDA is the potential to increase selective pres-
sure on the parasite and thus accelerate the emergence and
spread of drug resistance. In the case of falciparum malaria, such
reservations are compounded by the prospect of resistance to
artemisinin-based therapies, which are generally the ﬁrst-line
treatment.1 Several strategies, as used in TME, are available to
mitigate the emergence of resistance: 1. target patients with very
low parasite densities (subclinical infections) and 2. reduce the
time period between rounds of MDA to reduce the ﬁtness advan-
tage for novel resistant falciparum strains or the ampliﬁcation of
already resistant strains.1
Concurrently, to maximize the chance of interrupting local mal-
aria transmission, models indicate that coverage in target commu-
nities must be >80%.16,19,21 Particularly in the isolated and mobile
communities where transmission is focused throughout the GMS,
this is a logistical challenge.22–30 Based on such perceived risks,
policymakers have been hesitant to support MDA for malaria pre-
vention and control.
Considering the urgent need for accelerated malaria elimin-
ation in the GMS, it is critical to explore the current views and
perceptions towards MDA. However, little has been reported
regarding the views of key stakeholders towards MDA for mal-
aria elimination: how do policymakers and malariologists view
MDA as an approach? How important are concerns about the
inadvertent spread of resistance? What do they see as the main
implementation challenges? What evidence would require pol-
icymakers to implement MDA as a malaria elimination strategy?
Drawing on in-depth interviews, this article explores the atti-
tudes of policymakers and leading malariologists towards MDA
for malaria elimination.
Methods
Data collection was conducted between October 2016 and April
2017 at various locations in Thailand, Myanmar, Cambodia,
Laos, Vietnam and the USA.
Respondents
Respondents were recruited based on their expertise (principal
investigators of current malaria elimination studies and senior
malariologists) or decision-making roles in malaria prevention,
control and elimination in the GMS (policymakers in Thailand,
Cambodia, Myanmar, Vietnam and Laos, and funders, such as
from the World Health Organization [WHO] and the Bill and
Melinda Gates Foundation) (Table 1). Potential respondents were
identiﬁed through a combination of a snowball approach and bibli-
ography and web searches. A snowball approach was used to
overcome the difﬁculties contacting and setting appointments with
respondents who have busy schedules. The appropriateness of
potential respondents identiﬁed during interviews or web searches
was discussed among core members of the research team.
The contact details of potential respondents were obtained
from institutional websites or from other respondents. Potential
respondents were subsequently contacted by e-mail. None of
the potential respondents explicitly refused to participate; two
potential participants did not respond to the approaches or
failed repeatedly to keep arranged appointments. Neither
offered a reason for this.
Semi-structured interviews (SSIs) were conducted until a
point of theoretical saturation was reached, i.e. when no novel
information emerged from the data.31 Seventeen interviews
were conducted with policymakers/funders and 24 were con-
ducted with study principal investigators/senior malariologists.
Data collection
Whenever possible, interviews were conducted face to face at
one of the TME study sites, selected international tropical medi-
cine conferences or at the ministerial ofﬁces of the respective
country. If a face-to-face meeting was not possible, Skype or
telephone interviews were conducted. Two respondents were
Table 1. Characteristics of respondents
Policymakers Principle investigators
17 15
8 were national and 9 were
international
2 were national and 13 were
international
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not available for an interview and responded to an e-mail
questionnaire.
All interviews were conducted in English by the ﬁrst author.
Interview length ranged from 20 to 90 min. On average, interviews
with policymakers and funders were longer than those with scien-
tists. Interviews were audio recorded and transcribed verbatim by an
independent transcriber and all transcripts were checked for quality.
During the interviews, a semistructured interview guide was
used to direct questioning. Topics included malaria elimination,
MDA and community engagement. Under these broad topics, a
ﬂexible and iterative approach was taken to questioning to elicit
in-depth information and to ensure that relevant topics were
not neglected.
Data analysis
The interview transcripts were analysed using qualitative data
analysis software (NVivo 11; QRS International, Burlington, MA,
USA). A codebook adapted from previous qualitative research on
TME and community engagement (in Cambodia, Laos and
Myanmar) was used. Line-by-line coding of transcripts was con-
ducted using these pre-established themes (deductive
approach, e.g. malaria elimination, community engagement,
MDA), followed by themes that emerged during the data ana-
lysis (inductive approach). Analysis continued by identifying and
explaining prominent themes, patterns among respondents and
outliers. To ensure coding reliability, all coding was initially done
independently and then collectively discussed and agreed on.
Emerging themes were discussed among members of the study
team before further integration.
Ethics approval
Ethical approval was obtained from the Oxford Tropical
Research Ethics Committee (OxTREC) and approved on 31
January 2017 (Unique Protocol ID: OxTREC ref: 5122-16). Verbal
informed consent was obtained from all respondents prior to
interviews.
Results
Respondents included eight policymakers from six countries and
nine representing international health institutions. Nine of the
principal investigators/senior malariologists were connected to
recent TME pilot studies of MDA for malaria elimination in the
GMS region and six were connected to other international
research institutes in the USA, UK, Japan and Australia.
Scientists and policymakers discussed their experiences and
familiarity with MDA (Figure 1) and the challenges associated
with its implementation, including acceptability (Figure 2). All
respondents were familiar with MDA, mostly as a tool for con-
trolling other tropical diseases, such as microﬁlariasis, schisto-
somiasis and helminthic diseases. Sixteen respondents were
familiar with the TME pilot studies.
Most respondents described concerns about malaria elimin-
ation through MDA. They raised four types of issues related to
Figure 1. Geographic diversity and distribution of respondents in the study (red marks represent respondents’ locations).
N. Kaehler et al.
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1. the science of MDA, its rationale and possible ramiﬁcations
(amount of work involved, safety concerns and resistance);
2. national and local politics; 3. appropriate locations for MDA,
including population mobility; and 4. how to roll out MDA.
The science of MDA, its rationale and possible
ramiﬁcations
Most policymakers and some researchers described concerns
around the evidence base for MDA for malaria control and elim-
ination. Although potentially a useful tool, they cited a lack of
evidence regarding its effectiveness and appropriate circum-
stances, particularly in terms of malaria transmission dynamics.
Scientists highlighted the importance of choosing the right
drug combination for effective MDA. With regard to possible drug
combinations for MDA, most researchers reported that DHA-PPQ
(as used in TME) was appropriate, because there was enough
safety evidence. Some researchers suggested that, in the future,
increasing resistance to current drugs will necessitate the use of
three antimalarials in combination. Others considered existing
combination therapy sufﬁcient for the elimination of low-density,
subclinical infections. Triple therapy may be more appropriate for
treatment of clinical infections with higher parasite densities.
In the TME studies, single, low-dose primaquine to suppress
gametocytaemia was used in addition to DHA-PPQ (with the
exception of Cambodia, where regulatory approval to use prima-
quine was not given). Respondents recognized that using prima-
quine for radical therapy of Plasmodium vivax malaria (14 d
course) in glucose-6-phosphate-deﬁcient populations, however,
can potentially cause severe haemolysis. Some scientists men-
tioned the potential use of tafenoquine, referring to the ease of
administering it as a single-dose regimen. However, serious con-
cerns about haemolysis were expressed about this drug as well,
as it has a long half-life and once given cannot be ‘stopped’. In
addition, the lack of safety data on tafenoquine further restricts
its use and potential role in the future.
Most scientists and policymakers described a fear of MDA
increasing drug resistance and affecting the drugs available for
future treatment. The scientists involved with the recent studies
of MDA for malaria elimination in the GMS questioned the
assumption that increased drug use would lead to increased
drug resistance. Speciﬁcally, they described how administering a
complete treatment course is unlikely to increase the risk of
resistant strains emerging or becoming ampliﬁed.
Policymakers were unclear about the rationale for MDA as a
strategy to prevent the spread of resistance. According to some
researchers, the potential catastrophic outcome of the spread
of resistant parasites was not taken as seriously as the circum-
stances require.
We failed to convince them [the policymakers] that it is
urgent. And so I think it’s too late now because resistance
has continued to spread and it’s probably now going to fol-
low its natural course to India, Bangladesh and then Africa.
—SSI with a malariologist (#27)
Political challenges
Most respondents described political challenges at all levels:
from the highest level of policymaking to the target communi-
ties. Researchers described primarily challenges connected to
studies of MDA, whereas most policymakers referred to chal-
lenges in connection with MDA implementation within malaria
control programmes. In regard to studies of MDA, political chal-
lenges were described from the initial phase of seeking ethical
approval to the ﬁnal steps before study initiation. Seeking gov-
ernment approval was considered critical but time-consuming.
A factor mentioned to inﬂuence this process was the selection
of key policymakers (for instance, members of the ministry of
health and heads of departments of parasitology and malaria)
responsible for decision making.
In general, scientist respondents linked the delays to a mis-
understanding about the purpose of the TME pilot studies, with
policymakers regarding them as a strategy to implement MDA
rather than research studies to assess efﬁcacy and feasibility.
The lack of policy support due to apparent misunderstanding
varied across the countries. At the national level, scientists
reported unknown factors underpinning governments’ support
or opposition to an MDA trial, particularly because sometimes
decisions changed suddenly without any speciﬁc reason.
We talked about mass drug administration, and people like
the head of the malaria control programme was adamantly
against it, and other people were also kind of saying, ‘Over
my dead body,’ basically, but that changed within two
years…they didn’t give any speciﬁc reasons for it. It’s kind
of a belief system.
—SSI with a malariologist (#32)
Science of MDA
(Lack of adequate
evidence, fear of drug
resistance)
Characteristics of
population and the
context
(Migration and
mobility, accessibility,
structural and local
politics, rumors,
religion and beliefs)
Practical 
challenges/Unanticipated 
challenges 
Reluctance to
consider the
approach and
its implementation 
Difficulty enrolling,
opposition and
achieving targeted
population coverage 
Failure to convince 
the policy makers,
can lead to
opposition at
structural level and
opposition from
population 
Delay and reluctance
in implementation;
Poor acceptability
and low population
coverage;
inadvertent
consequences
leading to failure  
Figure 2. Suggested factors affecting implementation and acceptability
of MDA.
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There were less ambiguous reasons underpinning some decisions
regarding national-level MDA research. One country had reportedly
decided to support an MDA study, yet when a former but still inﬂu-
ential politician suddenly opposed the study, the decision was
reversed. Several researchers blamed the WHO’s initial lack of sup-
port for MDA as prompting several GMS states to delay MDA trials.
In Myanmar and Vietnam, where the government had already
approved an MDA study, the opposing parties suddenly objected to
studies, citing the lack of a WHO recommendation.
Political division in communities reportedly also impacted the
success of several MDA studies. One researcher described how
along the Thai–Myanmar border, strong political divisions and
refusal to participate in MDA by one half of the community who
were afﬁliated with a particular political party detrimentally
affected the study outcome.
Appropriate locations for MDA
Mobility and migration
Respondents were concerned about the mobility of target popula-
tions, which often cross national and international borders in search
of work, health care and security. This was considered a prominent
challenge to interrupting malaria transmission. Community mem-
bers who are busy with agricultural work (mostly rice plantation) in
the ﬁelds during rainy seasons can miss part of all components of
the MDA and were viewed as presenting a speciﬁc challenge.
High-risk populations, living and working in and around for-
ests, where malaria has been linked to occupations, such as log-
ging, hunting and farming, were also seen as a particular
challenge. One scientist pointed out that transmission often
does not occur within the villages but more commonly in the
forests, requiring that subjects would have to pass through such
sites and get infected before they can subsequently spread fur-
ther the infection within the village. In regard to the impact of
mobility on MDA, the risk of new infections is therefore lower
than anticipated, as not all mobile subjects have passed
through an area of transmission and therefore do not import
new malaria parasites to the community.
Geographically conﬁned territories, such as islands, were con-
sidered more appropriate sites for MDA because of the ease of
monitoring mobility in target communities.
SSI-P25: I said what I would prefer is to go to a road, take
the end of the road, 10 villages and do it there. The only
thing that you have to control is this [mobility]. There will
be less migration [mobility].
To overcome challenges of mobility, one policy maker suggested
massively scaling up the target areas but at the same time
emphasized the consequential need for mobilizing signiﬁcant
resources. Several scientists were conﬁdent that the challenge
posed by mobility can be overcome by a well-functioning detec-
tion and treatment system.
Remoteness and isolation of target communities
Scientists and policymaker agreed that selecting a site appropri-
ate for MDA was a prominent challenge. It was generally agreed
that MDA is effective in low-transmission settings, including in
urban areas.
In the GMS, transmission often occurs in forested regions,
which are difﬁcult to access. This remoteness was reported to
have caused difﬁculties with recruitment of staff willing to
undertake the necessary long and difﬁcult journeys, accept
arduous working hours and live under basic living conditions for
days or weeks. Also, when choosing sites for the pilot studies,
remote, villages with poor accessibility had to be excluded as
the blood sample collection and processing had to be com-
pleted within 24 h and could not be performed on site.
How to roll out MDA
Acceptability in target communities
One respondent described how a rumour started by a single
person could apparently affect population coverage in the pilot
studies. In addition, negative experiences with past MDAs were
described as having often caused problems. For instance, in
Cambodia, several people became ill after an MDA some years
ago, and this prompted a strong aversion to MDA in local com-
munities (and among policy makers). Stories of a death linked
to an MDA in Myanmar had a similar impact.
SSI with a senior policy maker (#12): …that there was an
MDA project I think back in the end of the last decade in
Myanmar and there was a death basically, …he was saying
that at that moment people were saying let’s NOT go for
MDA, ....there was such a push back because publicity was
like you can kill people, so let’s not move in that direction.
Researchers raised the importance of community engagement
to respond to such issues, and study staff could talk to mem-
bers of target communities and address directly their concerns.
Some researchers mentioned that inadequate attention to com-
munity engagement (that entailed helping the target population
to understand the study rationale and outcome) can jeopardize
the MDA. Others referred to a lack of staff and representatives
at the community level to answer and respond to such rumours.
Indeed, most researchers viewed the collaboration of commu-
nity members, through active training and jointly executing the
MDA, as a key element of community engagement. Amongst
the manifold beneﬁts of community collaboration, the sense of
ownership felt by the community in jointly undertaking MDA
was described as critical.
Some respondents also highlighted the complexity of the
concept of asymptomatic malaria infection and the difﬁcul-
ties that the target populations had in understanding this.
Hence, motivating local community members who were
seemingly healthy to participate in MDA was recognized as a
difﬁcult task.
Also, the presence of staff to monitor and address
adverse events during and after MDA was considered crucial
to avoid potential drop-outs and rejections. Researchers
added that this was relevant regardless of whether the ‘per-
ceived side effects’ were directly related or otherwise to the
drugs.
N. Kaehler et al.
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Seasonal timing of MDA
Seasons reportedly had a double impact on MDA. Around the rainy
season (just before or after), when malaria incidence is highest, is
regarded to be the best time to perform MDA in terms of clearing
parasites. However, in this period, many villagers are occupied with
agricultural work and may be unavailable for several weeks.
Additionally, during the rainy season, access to the villages is often
severely compromised due to worsening of road conditions.
SSI with a malariologist (#30): It’s very difﬁcult in [this
country]. Many—the road system has improved in my time
here, but there are still—in the rainy season, quite large
Table 2. Summary of meetings and published documents on MDA before the interviews
Year Event MDA-related content Participants
2013 Meeting for operational research on malaria
elimination, October 2013, Geneva, Switzerland
Meeting: discussion of the optimal MDA strategy (i.e.
timing, duration, combinations of drugs, number
of treatment rounds, demographically and
geographically deﬁned at-risk populations,
monitoring of adverse events and population
acceptability)
Senior researchers and
government ofﬁcials
2013 ASTMH Annual Meeting,Washington DC, USA,
November 2013 (Available at: http://www.
abstractsonline.com/Plan/ViewSession.aspx?sKey=
2ae4d000-e718-4bce-8464-20085506c849&
mKey=%7bCEAFE81A-9B33-4623-A1BB-
85D31108B94B%7d)
Symposium: Implementation of Mass Drug
Administration for Malaria Control and Elimination
(7 presentations)
Senior researchers,
government ofﬁcials,
NGOs; open to the
public
2014 National Malaria Research Network of Cambodia
Workshop, July 2014
Update on clinical studies: MORU presented its
experiences with TME along the Thai–Myanmar
border. TME was found to be best way to target
villages effectively
Senior researchers and
government ofﬁcials
2014 Workshop on Targeted Mass Treatment for Malaria
Elimination, Phnom Penh, November 2014
Workshop MDA/TME Senior researchers,
government ofﬁcials,
NGOs
2014 ASTMH Annual Meeting, New Orleans, LA, USA,
November 2014 (http://www.abstractsonline.com/
Plan/SSResults.aspx)
Symposium: Recent Experiences of Using Targeted
Mass Treatment with Antimalarial Drugs for
Parasite Clearance from the Human Reservoir in
Southeast Asia and Africa (6 presentations)
Senior researchers,
government ofﬁcials
and NGOs; open to the
public
2015 ASTMH Annual Meeting, Philadelphia, PA, USA,
October 2015 (http://www.abstractsonline.com/
Plan/ViewSession.aspx?sKey=a6ecff33-a023-
4961-8be7-a7cecae1b56c&mKey=%7bAB652FDF-
0111-45C7-A5E5-0BA9D4AF5E12%7d)
Symposium: Current Lessons from Drug-Based
Strategies for Malaria Elimination
Senior researchers,
government ofﬁcials
and NGOs; open to the
public
2016 Mass Drug Administration WHO Policy Update
(Global Malaria Program), May 2016, Bogota,
Colombia (http://www.paho.org/hq/index.php?
option=com_docman&task=doc_view&gid=
34878&Itemid=270&lang=pt)
Dr A. Bosman, Global Malaria Program and WHO:
‘The new WHO recommendations on MDA’
Senior researchers,
government ofﬁcials
and NGOs
2016 ASTMH Annual Meeting, Atlanta GA, USA, November
2016 (http://www.abstractsonline.com/pp8/
#!/4114/)
Sessions:
• Malaria: Epidemiology I—Intervention Studies and
Evaluation (session 5)
• Malaria Elimination Strategies Using Targeted
Mass Drug Administration: Lessons from the Field
(session 55)
• Integration of Mass Drug Administration with
Vector Control Approaches: An Enhanced Malaria
Elimination Package (session 96)
Senior researchers,
government ofﬁcials
and NGOs; open to the
public
ASTMH: American Society of Tropical Medicine and Hygiene; MORU: Mahidol-Oxford Tropical Medicine Research Unit; NGOs: non-governmental
organizations.
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communities—difﬁcult to get into and resupply because of
landslides and overﬂowing rivers, etc.
In the rainy season, seasonal illnesses, such as acute respiratory
tract infections, were sometimes misinterpreted as side effects
of the MDA drug. This was compounded if supervision and con-
sultation after MDA was insufﬁcient.
Discussion
This is the ﬁrst article to explore policy makers’ and leading
malariologists’ views on research into and the use of MDA for
malaria elimination. The ﬁndings highlight different opinions
between policy makers and researchers. Although most respon-
dents echoed the challenges associated with implementation of
MDA, national and international policy makers were particularly
sceptical about applying this strategy for malaria elimination.
The ﬁndings highlight several areas for discussion: 1. the inhibi-
tory inﬂuence of the WHO on policy makers when forming their
opinions; 2. the impact of previous MDAs in inﬂuencing attitudes
to MDA, which were often intertwined with local politics; and
3. challenges identifying appropriate sites for MDA.
Evidence and the role of the WHO
Several policy makers were unclear about the rationale for MDA as
a tool for malaria elimination. This was in spite of the topic having
been discussed by senior researchers, governmental ofﬁcials, and
NGO staff during at least one international meeting every year in
the GMS and at every ASTMH conference between 2013 and 2017
(Table 2). Two major systematic reviews of clinical research on
MDA have been published,19,21 and two have addressed the role
of community engagement in MDA16,32 (Table 3). Also, in late
2015, for the ﬁrst time, the WHO published a recommendation on
the use of MDA in malaria elimination based on a recent review of
evidence33 and the advice of the Malaria Policy Advisory
Committee which took place in April 2015.34
Despite the evidence regarding the importance of the sub-
clinical parasite reservoir and the potential strategies to address
this, the concept of asymptomatic malaria/sub-clinical malaria
reservoir is still a relatively new concept for many policy makers.
Moreover, policy makers are often guided by national malaria
reports that focus on the incidence of clinical cases as a key
indicator of success. For them, addressing asymptomatic cases
therefore might be a low priority.
Other challenges, for example in Myanmar, included policy
makers seemingly misunderstanding the TME pilot studies as a
malaria control strategy.35 This delayed the pilot studies and
the generation of evidence regarding the effectiveness of this
approach.
The WHO’s initial hesitation to support MDA as a tool for mal-
aria control was reﬂected by the decision to oppose MDA made
by several countries in the GMS, even at an experimental stage.
Following the WHO’s 2015 supportive recommendations to
include MDAs as a malaria control and elimination tool,33 more
countries began to consider MDA as a potential tool for malaria
control programmes.
Politics and the legacy of past MDAs
Both researchers and policymakers recalled their past experi-
ences of MDAs and acknowledged the challenges in the ﬁeld.
The tragedy of an unpublished 2008–9 MDA in Cambodia, during
which hundreds of patients were hospitalized, inﬂuenced the
attitudes of policymakers and caused signiﬁcant delays to the
TME pilot study in that country.22 Recently conducted MDAs in
the GMS that used DHA-PPQ as an antimalarial did not show
any cardiotoxicities.12–14 A recent systematic literature review
on the safety and efﬁcacy of DHA-PPQ echoed these ﬁndings.15
Negative experiences of past MDAs for other diseases also inﬂu-
enced attitudes in target communities.36
Politics played a role among policymakers, for example in
Myanmar and Vietnam, where opposing parties’ objections led
to delays in approval of the pilot studies. Political divisions within
target communities were also relevant; for example, close to
the Thai–Myanmar border, where political afﬁliations prevented
half of the villagers from participating in the MDA.29
Choosing appropriate sites for MDA
Many potential sites for MDA in the GMS include populations
that are mobile. This has been identiﬁed as a critical factor
affecting the coverage of MDA and its impact of transmis-
sion.19,21,36,37 On Aneityum Island, where MDA for malaria elim-
ination was successful, a rigorous system of detection and
treatment of all persons coming to the island was attributable
to its success.38,39 In settings where population movements can
be monitored, for example in remote highlands and small
islands, MDA is more likely to have a sustained impact on mal-
aria transmission than in well-connected areas.19,21 These ﬁnd-
ings and the fact that many malaria endemic settings are often
located in remote areas within the GMS, policymakers might
have prompted doubts about the feasibility, uptake and poten-
tial beneﬁts of MDA. Given that MDA requires an intensive
approach to achieve high population coverage and adherence,
the challenges for policymakers of implementing MDA in such
settings might have outweighed the beneﬁts of testing both a
pilot TME study12,13 and its roll out.14
It was generally agreed that MDAs would only be effective in
low transmission areas.19,21,36 However, working in these loca-
tions often involves many challenges: accessibility due to distant
location, bad or non-existing roads, seasonal ﬂooding, etc.22,25
In these remote populations, additional challenges include low
levels of literacy, lack of primary health care, and language and
communication issues.16,22,23,25–29,32,35
The importance of choosing the right season for MDA is a
major factor. The best time of year to implement MDA is generally
considered to be during or after the rainy season, when malaria
transmission is high, as highlighted in a recent MDA from
Cambodia.22,24 However, in settings where the agricultural work-
load is largely correlated with the rainy season,22,25 an MDA can
interrupt the work of community members and may not receive a
high priority. Accessibility to these villages because of poor road
conditions and ﬂooding is even worse during the rainy sea-
son.25,28,29 In Cambodia, several villagers suffered from seasonal
ﬂu but attributed the symptoms to the MDA drug they had taken.
This subsequently had a strong negative impact on participation.22
N. Kaehler et al.
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Table 3. Summary of published documents discussing MDA before the interviews
Author, year Title Content on MDA Characteristics of published literature
Atkinson et al.,
201132
The architecture and effect of participation: a
systematic review of community participation for
communicable disease control and elimination;
implications for malaria elimination
Systematic review focusing on the importance of
community participation for communicable
disease control and elimination (including MDA)
Accessible on PubMed
Poirot et al.,
201321
Review—Mass drug administration for malaria Systematic review on MDA. This review concluded
that MDA can quickly reduce malaria parasitaemia
as well as improve several clinical outcomes. More
studies are needed to assess its impact after 6
months. Furthermore, the barriers for community
uptake as well as the potential contribution to the
development of drug resistance need to be
explored
Accessible on PubMed
Newby et al.
201519
Review—Mass drug administration for malaria and its
operational challenges
Systematic qualitative review of published,
unpublished and grey literature documenting past
MDA experiences.
Information was also acquired through consulting
with ﬁeld experts, exploring their historical
experience to provide an informed and contextual
perspective on the role of mass drug
administration in malaria elimination.
Knowledge gaps remain and more research is
necessary, particularly on the optimal size of the
target population, primaquine safety and effective
methods to improve population coverage. Despite
these gaps, MDA has been shown to be successful
in controlling and eliminating Plasmodium
falciparum malaria as well as Plasmodium vivax
malaria. MDA should therefore be considered as
part of a comprehensive malaria elimination
strategy in speciﬁc settings
Accessible on PubMed
von Seidlein et al.
20151
Review—Fighting ﬁre with ﬁre: mass antimalarial
drug administrations in an era of antimalarial
resistance
Review on MDA.
Recent emergence of artemisinin-resistant P.
falciparum is of greatest concern. If ongoing efforts
to contain artemisinin resistance are successful, it
has yet to be shown.
Currently, with no other promising plans to eliminate
falciparum malaria from foci of artemisinin
resistance, using a multipronged approach
including MDA has been suggested. MDA is
controversial, as it may increase drug pressure. It is
difﬁcult to conceptualize how TME may contribute
Accessible on PubMed
Continued
InternationalH
ealth
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Table 3. Continued
Author, year Title Content on MDA Characteristics of published literature
to increase artemisinin resistance, provided a full
treatment course is given
2015 WHO Recommendations on MDA (2015, 2017)
(http://www.who.int/malaria/publications/atoz/
role-of-mda-for-malaria/en/)
The recommendations are based on a recent review
of evidence (Mass drug administration, mass
screening and treatment and focal screening and
treatment for malaria. WHO Evidence Review
Group meeting report, WHO Headquarters, Geneva,
20–22 April 2015) and the advice of the Malaria
Policy Advisory Committee
Accessible on the WHO homepage
2017 Operational Manual on MDA for falciparum malaria
(2017) (http://www.who.int/malaria/mpac/mpac-
mar2017-MDA-draft-manual-session7-
presentation.pdf)
Manual on practical strategies for MDA for falciparum
malaria
Accessible on the WHO homepage
Adhikari et al.
201616
Review—Community engagement and population
coverage in mass anti-malarial administrations: a
systematic literature review
Review built on a previous review that identiﬁed 3049
articles describing MDAs published between 1913
and 2011. A total of 51 articles were retained for
analysis, describing population coverage and/or
community engagement in mass MDAs. Population
coverages were quantitatively assessed and a
thematic analysis explored community
engagement activities.
Further research is needed to better understand the
factors that inﬂuence adherence and population
coverage in MDAs and the role of community
engagement in satisfactory participation
Accessible on PubMed
N
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Strengths and limitations
Using a snowball approach to recruit participants facilitated
access to difﬁcult-to-reach policymakers involved in malaria pre-
vention and control in the GMS and key decision makers at large
international funders. Although such an approach has the
potential to bias the make up of the study respondents (e.g.
they might represent a particular subgroup of scientists with a
particular perspective on MDA), disagreement among respon-
dents, particularly regarding the key issue of whether MDA has
the potential to promote resistance, suggested that this was
not the case.
Conclusions
Although most respondents identiﬁed implementation chal-
lenges related to MDA, national and international policy-
makers were particularly sceptical about applying this
strategy for malaria elimination. The complex rationale of MDA
for malaria elimination, mistaking pilot studies for implemen-
tation, past experiences with MDA, difﬁculties in selecting
appropriate sites and the WHO’s lack of clear backing under-
mined support for this approach among policymakers. The
WHO’s role was pivotal and its change in stance towards MDA
for malaria elimination prompted a change in the opinions of
national policymakers.
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